BONE MARROW TRANSPLANTATION FOR HIV PATIENTS WITH CANCER

艾滋病毒癌症患者的骨髓移植

• 批准号: 3194411
• 负责人: RICHARD Frederick AMBINDER
• 金额: $ 21.05万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-02-17 至 1992-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3194411
• 关键词: AIDS therapy; Betaherpesvirinae; HIV infections; Kaposi's sarcoma; antiAIDS agent; antiviral agents; autologous transplantation; blood donor; bone marrow transplantation; busulfan; combination chemotherapy; communicable disease diagnosis; cyclophosphamide; cytogenetics; drug adverse effect; hematopoietic stem cells; homologous transplantation; human immunodeficiency virus 1; human subject; immunotherapy; microorganism disease chemotherapy; neoplasm /cancer immunotherapy; secondary infection; serotyping; virus DNA; whole body irradiation dosage; zidovudine

This project requests support for preclinical and clinical studies evaluating the role of bone marrow transplantation (BMT) and antiviral chemotherapy in the treatment of HIV-l positive patients with hematologic malignancy. Three specific aims are addressed. In Aim 1, we plan to determine whether intensive therapy followed by BMT can eliminate the reservoir of HIV-l infected cells and if 3'-azido-3'deoxythymidine (AZT) can prevent infection of transplanted donor cells obtained from allogeneic bone marrow. In Aim 2, we plan to determine which lympho-hematopoietic cells in HIV-l positive patients carry the virus to determine whether the virus is present in stem cells and what fraction of cells are infected with HIV-l in patients at different stages of their disease. In Aim 3, we plan to investigate whether pluripotent lympho-hematopoietic stems free of HIV-l can be generated with ex vivo bone marrow manipulation and "purging" techniques. If this aim is successful it will lead to consideration of autologous BMT as therapy for patients with HIV-l infection.

该项目请求临床前和临床研究支持 评估骨髓移植（BMT）的作用和 HIV-1阳性患者的抗病毒化疗 患有血液系统恶性肿瘤。 解决了三个具体目标。 在目标 1 中，我们计划确定是否遵循强化治疗 通过 BMT 可以消除 HIV-1 感染细胞的储存库，如果 3'-叠氮基-3'脱氧胸苷 (AZT) 可以预防感染 从同种异体骨髓中获得的移植供体细胞。 在 目标 2，我们计划确定哪些淋巴造血细胞 HIV-1阳性患者携带病毒以确定是否 病毒存在于干细胞中，以及细胞的比例是多少 不同阶段感染HIV-1的患者 疾病。 在目标 3 中，我们计划研究多能是否 可以用 ex 产生不含 HIV-1 的淋巴造血干 体内骨髓操作和“净化”技术。 如果这个 目标成功将导致考虑自体 BMT 作为 HIV-1 感染患者的治疗。